celerion
Translating Science to Medicine

Please join us for Celerion's Clinical Discussion Forum Dinner

Human ADME Studies: Design, Operation and Pharmacy Considerations

- Study Designs - Classic and Expanded Designs
- When to Consider a Microtracer Dose
- Steps to Prepare for ADME Study
- Operationalization of the ADME Study
- Nuclear Pharmacy and Compounding
- Updates to Sterile Compounding- Including New USP <800>

Event Details

Date: **Tuesday, September 17, 2019**

Time: 5:30-6:30 pm: Networking, Apps & Drinks
6:30 pm: Presentation & Dinner

Venue: **Viognier Restaurant**
222 East 4th Avenue
San Mateo, CA 94401

****Ample Parking Onsite at Draegers****

About The Speakers

Jennifer Foster, Pharm D, RP | Authorized Nuclear Pharmacist

- Pharm D, University of Nebraska Medical Center
- Authorized Nuclear Pharmacist, Purdue University
- Over 18 years of experience as Clinical Research Pharmacist in Charge at Celerion

Mike Di Spirito, MSc | Director, Clinical Pharmacology & Pharmacometrics

- Master of Science degree in Rehabilitation Science in the Faculty of Medicine at McGill University in Montreal, Canada
- The Director of Clinical Pharmacology & Pharmacometrics at Celerion
- Over the last 20 years, Mike has worked on hundreds of NDA-enabling studies

About The Host

celerion
Translating Science to Medicine

Celerion, a full-service, early clinical CRO, is the leader in accelerating development for Phase I-IIb. We enable our clients to make timely decisions with expert advice and high-quality data through our unique combination of medical expertise, clinical operations experience and scientific excellence. Celerion uses our experience, agility and innovation to help clients get their drug to market faster so they can start making a difference in people's lives.

To access our unique insights for successful drug development, please visit: www.celerion.com

Space is limited. Please RSVP to Aricia Pfaff, Senior Director of Business Development at Aricia.Pfaff@celerion.com by Friday, September 13, 2019.